Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT03664466

Astaxanthin Effects on Osteoarthritis Associated Pain and Inflammatory Indicators

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Saint Luke's Health System · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study is intended to assess the effects of astaxanthin use on pain, physical function, and inflammation as reflected by Patient-Reported Outcomes Measurement Information System (PROMIS) scores and levels of inflammatory biomarkers in subjects taking astaxanthin. If improvements in pain, function, and/or markers of inflammation could be demonstrated with the use of astaxanthin, this may suggest the potential for astaxanthin to be used in management of knee osteoarthritis (and possibly other forms of osteoarthritis) with less evident toxicity than seen with the presently available standard therapies (e.g. NSAIDS, opioids).

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTastaxanthinastaxanthin capsules 12 mg twice daily
OTHERPlaceboplacebo capsules twice daily

Timeline

Start date
2021-04-29
Primary completion
2022-01-25
Completion
2022-01-25
First posted
2018-09-10
Last updated
2022-04-19

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03664466. Inclusion in this directory is not an endorsement.

Astaxanthin Effects on Osteoarthritis Associated Pain and Inflammatory Indicators (NCT03664466) · Clinical Trials Directory